<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224911</url>
  </required_header>
  <id_info>
    <org_study_id>LITT Treatment</org_study_id>
    <secondary_id>14-000409</secondary_id>
    <nct_id>NCT02224911</nct_id>
  </id_info>
  <brief_title>Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer</brief_title>
  <acronym>LITT</acronym>
  <official_title>Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, feasibility/exploratory study to evaluate the safety of laser interstitial
      thermal therapy (LITT) using Visualase in the focal treatment of localized prostate cancer as
      well as to gather data for the design of future studies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 11, 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of prostate cancer in the MRI target area as measure of efficacy.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Laser Interstitial Thermal Therapy</arm_group_label>
    <description>This is a minimally invasive procedure for focal treatment of prostate cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Interstitial Thermal Therapy</intervention_name>
    <arm_group_label>Laser Interstitial Thermal Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men, 40 to 85 years of age, recently diagnosed with prostate cancer using the MRI fusion
        technology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with initial presentation of organ confined prostate cancer (clinical stage ≤
             T2b)

               -  Negative metastatic workup with bone scan and CT abdomen/pelvis, within 6 months
                  of study treatment, if indicated by PSA &gt;10

               -  Age 40 years to 85 years of age

               -  Multi-parametric MRI at UCLA within 6 months of study treatment, demonstrating a

                    -  Region of interest (ROI) of MRI suspicion level 3 or higher

                    -  ROI located proximal to the external sphincter by a margin of at least 2 cm

               -  Transrectal ultrasound-guided biopsy with ≥ 10 systematic biopsy cores and ≥ 2
                  MRI-ultrasound fusion targeted biopsy cores from above MRI-derived ROI

                    -  Histologically-confirmed adenocarcinoma from targeted biopsy cores (≥ 2
                       cores)

                    -  Overall Gleason score not to exceed 3+4

               -  Subjects desire focal therapy and declined conventional treatment (active
                  surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone
                  therapy)

               -  Signed informed consent for the LITT treatment through the 12 month follow up
                  visit

        Exclusion Criteria:

          -  Any significant cancer outside of MRI target (ROI) area, defined as Gleason score &gt;
             3+4

          -  &lt; 10 years life expectancy

          -  American Society of Anesthesiologists (ASA) criteria of IV or higher

          -  Unfit for conscious sedation anesthesia

          -  Active bleeding disorder as determined by abnormal prothrombin time, partial
             thromboplastin time, INR or platelet count (as determined by institutional lab
             parameters) at the time of screening

          -  Use of coumadin or any other anticoagulant, unless anticoagulation can be temporarily
             reversed or stopped for a window of at least 7 days peri-procedure

          -  Active urinary tract infection

          -  Prostate abscess, chronic or acute prostatitis, or neurogenic bladder

          -  Any prior treatment for prostate cancer

               -  Radical prostatectomy

               -  Radiation therapy (external beam or brachytherapy)

               -  Cryotherapy

               -  High intensity focused ultrasound treatment

               -  Photodynamic therapy

               -  Androgen deprivation therapy

          -  Prior prostate, bladder neck, or urethral stricture surgery

               -  Any prostate debulking procedure, including: transurethral resection of prostate,
                  photovaporization, or electrovaporization

               -  Transurethral incision of bladder neck

               -  Urethral stricture dilation or reconstruction

          -  Any current 5-alpha reductase inhibitors (history of use ≥ 6 months prior to MRI is
             acceptable)

          -  Prior significant rectal surgery (hemorrhoidectomy is acceptable)

          -  Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding insertion
             of transrectal device

          -  History of inflammatory bowel disease

          -  Urinary tract or rectal fistula

          -  Any contraindication to MRI (contrast allergy severe claustrophobia, MRI-incompatible
             prosthesis)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pantuck Alan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Raman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.</citation>
    <PMID>23335087</PMID>
  </reference>
  <reference>
    <citation>Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5. Epub 2007 Oct 22.</citation>
    <PMID>17936806</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>focal therapy</keyword>
  <keyword>prostate cancer treatment</keyword>
  <keyword>laser treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

